user
menu
letter
Sign InRegister
langEnglisharrow

DLL3

DLL3

DLL3 Overview

Molecule Name
Delta-like protein 3
Synonyms
Delta3,delta-like 3 (Drosophila),delta-like protein 3,DLL3,Pudgy,SCDO1,SCDO1delta3
Drug Development Progress
Drugs in Clinical Trials30
Approved Drugs1
Highest Development StageApproved
Target Synonym
Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3
Background
Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands.May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues.

DLL3 Product List

Species
  • Human（19）
  • Cynomolgus（4）
  • Mouse（1）
  • Rat（1）
  • Rhesus macaque（1）
Tag
  • His Tag（19）
  • His Tag & Avi Tag（2）
  • Mouse IgG Fc Tag（2）
  • -（1）
  • Fc Tag（1）
  • Llama IgG Fc Tag（1）
Host
  • HEK293（26）
Conjugate
  • Unconjugated（19）
  • Biotin-labeled（3）
  • AF647 Labeled（1）
  • APC Labeled（1）
  • FITC Labeled（1）
  • PE Labeled（1）
Grade
  • RUO（26）
Low Endotoxin
  • Yes（12）
  • No（14）
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
DLL3
HOTAIDD‑Ready
DL3-M52H9
Mouse DLL3 Protein, His Tag, low endotoxin (HPLC verified)
Mouse
HEK293
HPLCSDS-PAGE
ELISASPR

$375.00

100ug
DLL3
HOTAIDD‑Ready
DL3-C52H3
Cynomolgus DLL3 Protein, His Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR
Inquiry
100ug
DLL3
HOTAIDD‑Ready
DL3-H52H4
Human DLL3 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRTR-FRET

$415.00

100ug
DLL3
DL3-C52Ha
Cynomolgus DLL3 (27-490) Protein, His Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$385.00

100ug
DLL3
AIDD‑Ready
DL3-C52Hb
Cynomolgus DLL3 (27-488) Protein, His Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR

$395.00

100ug
DLL3
AvitagAIDD‑Ready
DL3-C82E9
Biotinylated Cynomolgus DLL3 Protein, His,Avitag™ (SPR verified)
Cynomolgus
HEK293
SDS-PAGE
ELISASPR

$415.00

25ug
DLL3
DL3-H5243
Human DLL3 Protein, His Tag (HPLC verified)
Human
HEK293
HPLCSDS-PAGE
ELISA

$415.00

100ug
DLL3
DL3-H5256
Human DLL3 (353-427) Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$400.00

100ug
DLL3
DL3-H5259
Human DLL3 (353-465) Protein, Mouse IgG2a Fc Tag, low endotoxin
Human
HEK293
SDS-PAGE
ELISA

$400.00

100ug
DLL3
DL3-H525a
Human DLL3 Protein, Llama IgG2b Fc Tag, low endotoxin
Human
HEK293
SDS-PAGE
ELISA

$440.00

100ug
You Have Viewed 1-10 Of 26 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

Product InquiryRequest Customization
FAQ

What do SEC-MALS and SPR answer separately when qualifying a DLL3 reagent?

SEC-MALS assesses molecular weight and homogeneity in solution, whereas SPR confirms binding kinetics with a relevant antibody or ligand. Together they help separate aggregation-related signal from functional target recognition.

How should a DLL3 cross-reactivity panel be designed for preclinical development?

Compare human DLL3 with the homolog from the intended animal model, such as cynomolgus, rhesus, mouse, or rat. Use matched construct boundaries and assay formats so affinity differences reflect species rather than reagent design.

When should fluorescent DLL3 proteins or DLL3-coupled beads be used instead of unconjugated protein?

Fluorescent DLL3 supports direct flow-cytometric detection of DLL3-binding antibodies or engineered cells. DLL3-coupled beads are useful for binder capture, enrichment, or multivalent antigen presentation, while unconjugated protein remains preferable for quantitative kinetics.

How can soluble DLL3 protein and a DLL3 stable cell line be combined to reduce false-positive binders?

Use recombinant DLL3 for controlled affinity and epitope screening, then confirm hits on a DLL3 stable cell line. This filters candidates that recognize an isolated or tag-dependent epitope but poorly bind cell-surface DLL3.

How should I choose among full extracellular DLL3 and shorter DLL3 fragments for antibody discovery?

A broad extracellular construct is suitable for immunization and primary screening. Overlapping DLL3 fragments, such as residues 27–215, 176–492, and 353–492, can help localize epitopes before confirming binding to full-length cell-surface DLL3.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Zocilurtatug pelitecanZL-1310; YL-212Phase 3 ClinicalZai Lab (Shanghai) Co Ltd
Small Cell Lung Carcinoma; Solid tumours
Details
ObrixtamigBI-764532; OBT620Phase 3 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Carcinoma, Neuroendocrine; Glioma; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma
Details
AlveltamigZG-006; ZG006Phase 3 ClinicalGensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd
Carcinoma, Neuroendocrine; Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours
Details
89Zr-DFO-SC16.5689Zr-DFO-SC16.56Phase 2 ClinicalMemorial Sloan Kettering Cancer Center
Small Cell Lung Carcinoma
Details
GocatamigHPN-328; MK-6070; DS-3280Phase 2 ClinicalHarpoon Therapeutics
Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma
Details
EB-DART-NK01EB-DART-NK01Phase 2 ClinicalBeijing Biotech
Small Cell Lung Carcinoma
Details
4sCAR-DLL3 CAR-T Therapy (Shenzhen Geno-Immune Medical Institute)Phase 2 ClinicalShenzhen Geno-Immune Medical Institute
Glioblastoma; Melanoma
Details
SHR-7787SHR-7787; SHR7787Phase 2 ClinicalShanghai Hengrui Pharmaceutical Co Ltd
Small Cell Lung Carcinoma; Solid tumours
Details
SHR-4849SHR-4849; SHR4849; IDE849; IDE-849Phase 2 ClinicalJiangsu Hengrui Pharmaceutical Group Co Ltd
Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours
Details
DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital)DLL3-CAR-NK cellsPhase 2 ClinicalTianjin Medical University Cancer Institute And Hospital
Small Cell Lung Carcinoma
Details
PeluntamigPT-217Phase 2 ClinicalPhanes Therapeutics Inc
Carcinoma, Neuroendocrine; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours
Details
ML-261ML261; ML-261Phase 1 ClinicalMoonlight Bio Inc
Carcinoma, Neuroendocrine; Gastroenteropancreatic neuroendocrine tumor; Prostatic Neoplasms; Small Cell Lung Carcinoma
Details
NEUK203-13NEUK203-13Phase 1 ClinicalNeukio Biotherapeutics (Shanghai) Co Ltd
Neuroendocrine Tumors; Small Cell Lung Carcinoma
Details
111In-ABD147Phase 1 ClinicalAbdera Therapeutics Inc
Neuroendocrine Tumors; Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details
111In-ETN029111In-ETN029Phase 1 ClinicalNovartis Pharma Ag
Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma
Details
225Ac-ETN029225Ac-ETN029; [225Ac]Ac-ETN029Phase 1 ClinicalNovartis Pharma Ag
Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma
Details
HLX-3901HLX-3901Phase 1 ClinicalShanghai Henlius Biotech Inc
Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours
Details
177Lu-DTPA-SC16.56177Lu-DTPA-SC16.56Phase 1 ClinicalMemorial Sloan Kettering Cancer Center
Carcinoma, Neuroendocrine; Lung Neoplasms; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms
Details
SYS-6040SYS6040; SYS-6040Phase 1 ClinicalJushi Biopharmaceutical Co Ltd
Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours
Details
IBI-3009IBI3009; IBI-3009Phase 1 Clinical
Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours
Details
BL-M14D1BL-M14D1Phase 1 ClinicalBaili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd
Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours
Details
BHP-01BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-TPhase 1 ClinicalChengdu Brilliant Pharmaceutical Co Ltd
Small Cell Lung Carcinoma
Details
FZ-AD005FZ-AD005; FZAD005; F0041Phase 1 ClinicalShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Carcinoma, Neuroendocrine; Glioblastoma; Glioma; Small Cell Lung Carcinoma; Solid tumours
Details
[89Zr]Zr-BI-764532Phase 1 ClinicalBoehringer Ingelheim International Gmbh, C.H. Boehringer Sohn Ag & Co. Kg
Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma
Details
ABD-147ABD-147; 225Ac-ABD147Phase 1 ClinicalAbdera Therapeutics Inc
Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours
Details
SNC-115SNC115; SNC-115Phase 1 ClinicalShanghai Simnova Biotechnology Co Ltd
Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours
Details
RG-6524RO-7616789; ALPS-12; RG6524Phase 1 ClinicalF. Hoffmann-La Roche Ag
Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma
Details
OBT620OBT620Phase 1 ClinicalBoehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd
Small Cell Lung Carcinoma
Details
QLS-31904QLS-31904; QLS31904Phase 1 ClinicalQilu Pharmaceutical Co Ltd
Solid tumours
Details
LB-2102(Legend Biotechnology)LB-2102Phase 1 Clinical
Neuroendocrine Tumors; Small Cell Lung Carcinoma
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
TarlatamabAMG-757ApprovedAmgen IncImdelltraUnited StatesSmall Cell Lung CarcinomaAmgen Inc2024-05-16
Astrocytoma; Brain metastases; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Ganglioglioma; Glioblastoma; Medullary thyroid cancer (MTC); Melanoma; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Paranasal Sinus Diseases; Prostatic Neoplasms; Small Cell Lung Carcinoma; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
Customer Reviews